Updated: Mar 31
Manhattan, New York, New York – November 6th, 2020. Bridge Point Capital, a New York-based private equity firm focuses on U.S/Asia cross-border healthcare investments, today announced the appointment of two new strategic advisors – Ms. Gayatri Sarkar and Dr. Makarand Jawadekar.
Dr. Makarand Jawadekar is currently an independent Pharma Professional. He worked at Pfizer Inc. in Groton-New London, Connecticut, for 28 consecutive years. His most recent position was as a Director of Portfolio Management at Pfizer Inc. In the recent past, he was responsible for Drug Delivery Technology Assessment function involving external ‘Drug Delivery’ technologies. He has extensive experience in creating and cultivating external partnerships and alliances for drug delivery technologies. He began his professional career at Pfizer Central Research in early 1982, after having completed his Ph.D. in Pharmaceutics at the University of Minnesota. In February 2011, Mak was honoured with an honorary D.Sc. degree from DYP Mumbai University, recommended by the President of India.
As a “Bench Scientist”, he touched upon many challenging commercial formulations which became multibillion-dollar products for many years for Pfizer Inc. These R&D formulations & Product development programs included ZOLOFT, ZITHROMAX, VIAGRA faster onset & other successful products. He also worked on several “Life Cycle Management “projects for Pfizer’s existing ethical & OTC products. After retiring from Pfizer, he had an opportunity to work with KKR, a Private Equity group in New York, for acquisition of Capsugel division from Pfizer which Pfizer divested in 2011. Mak has presented at many professional meetings and has participated in various Panel Discussions/Round Tables around the globe during his Pfizer tenure. He currently serves on various Biotech/ Pharma company advisory boards and Boards of Directors.
Dr. Makarand Jawadekar is also a doctorate holder in Pharmaceutics from the University of Minnesota in Year 1982. With his knowledge and research work, Dr Jawadekar has involved himself in coming up with competitive & challenging commercial formulations, which now has become a successfully established line of multibillion-dollar products.
“We are more than excited to welcome Dr. Makarand Jawadekar to join us as an advisory. With his years of experience in this industry, we believe his professional knowledge, leadership and networks will benefit Bridge point Capital in a very special way”, said Mark Young, Founding Partner of Bridge Point Capital.
Ms. Gayatri Sarkar is the Managing Partner at Israeli fund HYPE Capital, venture arm of HYPE Sports Innovation, world's largest sports accelerator and Venture Partner at Nexgen, acquired by $72B Brown Advisory PE fund. Previously, she also served the Federal Reserve Bank, HP, IBM for many years.
Gayatri Sarkar is one of the few/only women of colour to become a General Partner at a Sports VC Fund. She is an experienced board of director in asset management firms and technology companies. She is championing investment mandates for women and diverse VCs through her She-VC podcast platform. She is a Managing Partner at HYPE Capital, venture arm of HYPE Sports Innovation, the world’s largest sports accelerator. Gayatri Sarkar is also a Venture Partner of early stage VC fund Nexgen Venture Partners, acquired by Brown Advisory with $72B AUM.
Previously, she was a GP at a Sports fund, venture arm of the NFL-A that was acquired. She managed multi-million-dollar enterprise data projects at the Federal Reserve Bank for the US military and Navy under US Treasury with big banks like JPM, PNC, G&D, Visa. Previously she worked for Hewlett Packard, IBM. She started her career as an Enterprise Data Architect. She is also a serial entrepreneur and founded a consulting company called Boston Consulting Solutions.
She is a graduate in Physics, Math and finance, along with a degree in MBA. Currently Ms. Sarkar is on the non-profit board of Harvard Kennedy School NEA. Ms. Sarkar was awarded Global Leader under 40 for championing women and diverse GPs/LPs through She-VC storytelling platform featuring a combined wealth of $200B.
“Ms. Sakar is an intelligent, knowledgeable & creative leader. Her energy and network will be a perfect fit for Bridge Point Capital. We can’t wait for her to contribute her fresh and unique insights to the company. Both as woman in the private equity space, I firmly believe this synergy would be tremendously helpful to the success of our firm”, said Nadia Tian, Founding partner of Bridge Point Capital.
Bridge Point Capital is a private equity firm based in New York, with a focus on U.S-Asia cross-border investments. We specialize with investing in disruptive late-stage healthcare companies, that can benefit from penetrating the vast, yet unexplored Asian healthcare market. We aim to leverage our expertise in both healthcare and capital markets, to establish a sustainable investment platform for our investors.